한국의약전달시스템학회 KCRS
home > 회원공간 > 자료실

자료실

 

   
  adult47.1000-agent.com김연아아사다마오의상비교 야동다운받는…
  글쓴이 : 퍄토요퍼14     날짜 : 23-11-29 08:00     조회 : 75    
adult47.1000-agent.com김연아아사다마오의상비교 야동다운받는곳 야플TV신도림동고스톱
야플TV<- 바로가기

SEOUL--()--Schneider Electric, the global leader in the digital transformation of energy management and automation that was recognized last February as the world’s most sustainable corporation in 2021 by the Corporate Knights Global 100 Index, and Alfa Laval, a leading global supplier of products and solutions for heat transfer, separation, and fluid handling, today announced that the companies have extended their partnership agreement to digitize and analyze data to improve Alfa Laval’s operational efficiency.

The two companies will use near real-time energy consumption data across sites, countries, and regions to identify and define energy efficiency projects. The collaboration is part of Alfa Laval’s efforts to become carbon neutral across the entire value chain by 2030.

“Accomplishing our carbon neutrality target will require efforts in our entire supply chain and enhanced collaboration with our customers, suppliers, and the societies in which we operate,” said Mikael Tyden, Executive Vice President, Head of Operations, Alfa Laval. “We have joined the Exponential Roadmap Initiative to support the implementation of energy-efficient solutions. Our extended partnership agreement with Schneider Electric is another concrete activity of reaching the 1.5°C scenarios set in the Paris Agreement.”

The partnership began in 2019 and was designed to digitize Alfa Laval’s energy infrastructure. Capturing energy consumption data across the business resulted in identifying energy efficiency projects and initiatives to reduce energy usage and cost across sites, countries, and regions. In this next step, the two companies will develop Alfa Laval’s roadmap towards extended use of renewable energy, switching from natural gas to other green alternatives. Alfa Laval has set a target of becoming carbon neutral by 2030 across the entire value chain, and this collaboration is an important step towards realizing this ambition.

“The time to take climate action seriously is now, particularly in light of the recent Intergovernmental Panel on Climate Change (IPCC) Sixth Assessment Report,” said Philippe Diez, Partner Sustainability Business Division Europe, Schneider Electric. “We are honored to join forces with Alfa Laval as the company moves beyond strategy and planning - and into implementation in pursuit of carbon neutrality across the value chain.”

For more information about Alfa Laval, visit alfalaval.com.Schneider Electric and Alfa Laval Extend Collaboration

CHALFONT ST GILES, ENGLAND--( / )--GE HealthCare today announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE), a Virginia, U.S.-based company, to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics targeting fibroblast activation protein 디시인사이드 모바일 남성자위 (FAP). Financial terms were not disclosed. Based on this agreement, GE HealthCare will take on global rights for [??Ga]FAPI-46 and outside-US rights for [¹?F]FAPI-74, originally developed at Heidelberg University in Germany, and both currently in Phase II clinical trials in the U.S. ([??Ga]FAPI-46 (NCT05262855)[2] and [¹?F]FAPI-74 (NCT05641896)[3]). SOFIE will continue its clinical development and commercialization program with [¹?F]FAPI-74 in the U.S.



FAP is an enzyme highly expressed in cancer associated fibroblasts (CAF), a key component of the tumor microenvironment which 디시인사이드 모바일 아줌마섹스 supports the growth and spread of cancerous cells. With CAF present in most tumor types including, for example, breast, pancreatic, colorectal, lung, liver and gastric, the development of FAP-targeted diagnostics holds great potential in 왕 뽕 비키니 FAPas well as other conditions including inflammation, fibrosis and arthritis[4].



Building on the momentum created by SOFIE’s sponsored trials in the U.S. and FAPI Global Outreach Program which engages with 130 academic institutions in 39 countries to unlock FAPI’s clinical utility, GE HealthCare 리얼돌멀티샵구매사이트 Buildingto develop FAP imaging products through clinical trials and towards regulatory submission, and potential commercialization in various regions. SOFIE and GE HealthCare will collaborate on both the development and commercialization processes through 디시인사이드 모바일 토렌트큐큐 a joint steering committee.



Usankar Thiru, Strategy & Evaluation Director with GE HealthCare’s Pharmaceutical Diagnostics segment said: “Working with SOFIE to add these FAPI assets to our next generation portfolio of investigational targets is a significant milestone and aligns with our vision to expand our innovation pipeline to enable precision care for personalized 야플TV 모노키니 treatment decision making. As a standalone company, we are keen to collaborate with companies like SOFIE in this way - bringing 텔레스코픽러버판매사이트 Usankarsize, scale and unique perspective as a developer, of both radiopharmaceuticals and 디시인사이드 모바일 the scanners needed to utilize them, to drive innovation in healthcare to benefit patients and clinicians.”



Sherly Mosessian, Ph.D, SOFIE’s Chief Scientific Officer, added: “The FAPI family 야플TV of compounds have shown to have tremendous potential in diagnostic and companion diagnostic use in various oncologic and non-oncologic indications. I am very excited that we are collaborating with GE HealthCare, on 디시인사이드 모바일 비키니라인왁싱 a worldwide scale, to help jointly unlock the full promise of these products.”



GE HealthCare’s Pharmaceutical Diagnostics segment is a global leader in imaging agents 야플TV 마블툰 used to support around 100 million procedures per year globally, equivalent to three patient procedures every second. Its 운교동홀덤 GEImaging portfolio combines established proprietary products across cardiology, 디시인사이드 모바일 보스토렌트 neurology and oncology.



About 디시인사이드 모바일 SAPJIwlC AboutHealthCare Technologies 디시인사이드 모바일 토렌트주 야플TV 토렌트주 Inc. 디시인사이드 모바일 편지지프린트



GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to 디시인사이드 모바일 색칠공부프린트 providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians 디시인사이드 모바일 야나무 more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, 디시인사이드 모바일 챔프코믹스 GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together 야플TV 회사네트워크공유 our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are an $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.



Follow us 구로동고스톱 Follow, , , , 디시인사이드 모바일 and Insights for the latest news, or visit our website for 디시인사이드 모바일 프린터공유하는방법 more information. 디시인사이드 모바일 프린터네트워크공유



About SOFIE 디시인사이드 모바일 네트워크프린터공유 Biosciences (SOFIE) 디시인사이드 모바일 딱좋은밤



SOFIE’s vision is to improve patient outcomes by developing and delivering molecular 중산동홀덤카페 SOFIE’sand therapeutics (theranostics). With 디시인사이드 모바일 러브82 its robust radiopharmaceutical production and distribution network, mature contract manufacturing services and high value theranostic intellectual property, SOFIE is poised to deliver 디시인사이드 모바일 on the promise of radiopharmaceuticals. 야플TV For more information visit our website, or contact us by email at info@sofie.com.



[1] Xing, F., Saidou, J. and Watabe, K. (2010) Cancer associated fibroblasts (cafs) in 경장동홀덤대회 [1]microenvironment, Frontiers in bioscience (Landmark edition). 디시인사이드 모바일 비비TV Available at: (Accessed: 28 July 2023).



[2] Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma (FAPI-46 PDAC) 디시인사이드 모바일 - Full Text View - ClinicalTrials.gov. (n.d.). (Accessed: October 4 2023).



[3] Study of [18F]FAPI-74 PET in Patients With Gastrointestinal 디시인사이드 모바일 NowGoal Cancers - Full Text View - ClinicalTrials.gov. (n.d.). (Accessed: October 4 디시인사이드 모바일 야후플리커 2023).



[4] Dendl, K., 디시인사이드 모바일 Koerber, S. A., Kratochwil, C., Cardinale, J., Finck, R., Dabir, M., Novruzov, E., Watabe, T., Kramer, V., Choyke, P. L., Haberkorn, U., & Giesel, F. L. (2021). FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A 디시인사이드 모바일 먹튀나라 Perfect Symbiosis? Cancers, 13(19), 4946. . Available at: (Accessed: October 4 2023).



View source version on businesswire.com:SOFIE and GE HealthCare Enter Licensing 디시인사이드 모바일 이마헤어라인 Agreement to Develop FAP PET Radiotracers